170 related articles for article (PubMed ID: 15123733)
1. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
Lev DC; Onn A; Melinkova VO; Miller C; Stone V; Ruiz M; McGary EC; Ananthaswamy HN; Price JE; Bar-Eli M
J Clin Oncol; 2004 Jun; 22(11):2092-100. PubMed ID: 15123733
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
Lev DC; Ruiz M; Mills L; McGary EC; Price JE; Bar-Eli M
Mol Cancer Ther; 2003 Aug; 2(8):753-63. PubMed ID: 12939465
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for melanoma: the resultant of conflicting vectors.
Mitchell MS
J Clin Oncol; 2004 Jun; 22(11):2043-5. PubMed ID: 15123732
[No Abstract] [Full Text] [Related]
4. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
5. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.
Luca M; Huang S; Gershenwald JE; Singh RK; Reich R; Bar-Eli M
Am J Pathol; 1997 Oct; 151(4):1105-13. PubMed ID: 9327744
[TBL] [Abstract][Full Text] [Related]
6. Parthenolide enhances dacarbazine activity against melanoma cells.
Koprowska K; Hartman ML; Sztiller-Sikorska M; Czyz ME
Anticancer Drugs; 2013 Sep; 24(8):835-45. PubMed ID: 23797801
[TBL] [Abstract][Full Text] [Related]
7. Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Crende O; Sabatino M; Valcárcel M; Carrascal T; Riestra P; López-Guerrero JA; Nagore E; Mandruzzato S; Wang E; Marincola FM; Vidal-Vanaclocha F
Am J Pathol; 2013 Jul; 183(1):69-82. PubMed ID: 23707237
[TBL] [Abstract][Full Text] [Related]
8. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Tsubaki M; Takeda T; Obata N; Kawashima K; Tabata M; Imano M; Satou T; Nishida S
J Cell Physiol; 2019 Aug; 234(10):17975-17989. PubMed ID: 30834527
[TBL] [Abstract][Full Text] [Related]
10. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
Zigler M; Villares GJ; Lev DC; Melnikova VO; Bar-Eli M
Am J Clin Dermatol; 2008; 9(5):307-11. PubMed ID: 18717605
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
12. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Valero T; Steele S; Neumüller K; Bracher A; Niederleithner H; Pehamberger H; Petzelbauer P; Loewe R
J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
[TBL] [Abstract][Full Text] [Related]
13. Role of interleukin-8 in tumor growth and metastasis of human melanoma.
Bar-Eli M
Pathobiology; 1999; 67(1):12-8. PubMed ID: 9873223
[TBL] [Abstract][Full Text] [Related]
14. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
15. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
[TBL] [Abstract][Full Text] [Related]
16. Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.
do Reis SRR; Helal-Neto E; da Silva de Barros AO; Pinto SR; Portilho FL; de Oliveira Siqueira LB; Alencar LMR; Dahoumane SA; Alexis F; Ricci-Junior E; Santos-Oliveira R
Pharm Res; 2021 Feb; 38(2):335-346. PubMed ID: 33604784
[TBL] [Abstract][Full Text] [Related]
17. Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
Roider E; Schneider J; Flaig MJ; Ruzicka T; Kunte C; Berking C
Int J Dermatol; 2012 Sep; 51(9):1142-4. PubMed ID: 21913905
[No Abstract] [Full Text] [Related]
18. Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.
Joukhadar C; Klein N; Mader RM; Schrolnberger C; Rizovski B; Heere-Ress E; Pehamberger H; Strauchmann N; Jansen B; Müller M
Cancer; 2001 Oct; 92(8):2190-6. PubMed ID: 11596037
[TBL] [Abstract][Full Text] [Related]
19. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
20. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8.
Schaider H; Oka M; Bogenrieder T; Nesbit M; Satyamoorthy K; Berking C; Matsushima K; Herlyn M
Int J Cancer; 2003 Jan; 103(3):335-43. PubMed ID: 12471616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
